Status:

COMPLETED

Study Evaluating Treatment of Upper Limb Spasticity Using the Cryo-Touch III Device

Lead Sponsor:

Pacira Pharmaceuticals, Inc

Conditions:

Upper Limb Spasticity

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

A proof of concept study to evaluate the feasibility of safe and effective treatment of upper limb spasticity using the Cryo-Touch III Device.

Detailed Description

Spasticity, common in neurological disorders, is part of the upper motor neuron syndrome displaying increased tone, clonus, spasms, spastic dystonia and co- contractions. The impact of spasticity on t...

Eligibility Criteria

Inclusion

  • Male or female, 18 years of age and older.
  • Trial participants must have a confirmed diagnosis that results in spasticity involving muscle innervated by the musculocutaneous nerve (MCN).
  • Any medications must be maintained on a stable schedule for at least two weeks prior to treatment. No washout period is allowed.
  • Must have an average score on the Modified Ashworth Scale for Spasticity of ≥ 2 over the last 30 days in the elbow.
  • Subject, in the Investigator's opinion, will not be exposed to unacceptable risk by participation.

Exclusion

  • Previous surgical intervention that altered the target neural anatomy of the upper limb.
  • Any injection (neurolytic, sclerosing, anesthetic, etc.) to the upper limb within the last 4 months.
  • Current enrollment in an investigational drug or device study that specifically targets spasticity management.
  • Allergy or intolerance to local anesthesia.
  • Any local skin condition at the treatment site that in the investigator's opinion would adversely affect treatment or outcomes.
  • Any chronic medication use (prescription, over-the-counter, etc.) that in the investigator's opinion would affect study participation or subject safety.
  • Diagnosis of cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's disease, open and/or infected wounds.
  • Diagnosis of progressive neurologic diseases such as ALS.
  • For any reason, in the opinion of the investigator, the subject may not be a suitable candidate for study participation (i.e., history of noncompliance, drug dependency, any related upper limb injury, etc.).

Key Trial Info

Start Date :

April 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2013

Estimated Enrollment :

19 Patients enrolled

Trial Details

Trial ID

NCT01863901

Start Date

April 1 2013

End Date

October 1 2013

Last Update

January 24 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Kansas City Bone and Joint Clinic

Overland Park, Kansas, United States, 66211

2

Dr. Mitchell Paulin

Paoli, Pennsylvania, United States, 19301